CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	DeepHealth, Inc.	Total Radnet, Inc.'s Equity	Common Stock	Common Stock DeepHealth, Inc.	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2022				57,723,125
Beginning balance at Dec. 31, 2022	$ 491,452		$ 332,995	$ 6		$ 436,288	$ (20,677)	$ (82,622)	$ 158,457
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)				5,000
Issuance of common stock upon exercise of options	51		51			51
Issuance of common stock under the equity compensation plan (in shares)				527,692	14,473
Stock-based compensation expense	12,185		12,185			12,185
Change in cumulative foreign currency translation adjustment	2,777		2,777				2,777
Change in fair value of cash flow hedge, net of taxes	0
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	922		922				922
Other	(3)		(3)			(2)		(1)
Net income (loss)	(14,283)		(21,005)					(21,005)	6,722
Ending balance (in shares) at Mar. 31, 2023				58,270,290
Ending balance at Mar. 31, 2023	$ 493,101		327,922	$ 6		448,522	(16,978)	(103,628)	165,179
Beginning balance (in shares) at Dec. 31, 2023	67,956,318			67,956,318
Beginning balance at Dec. 31, 2023	$ 813,359		630,695	$ 7		722,750	(12,484)	(79,578)	182,664
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)	1,000	4,393		1,299
Issuance of common stock upon exercise of options	$ 8		8			8
Issuance of common stock under the equity compensation plan (in shares)				616,767	4,393
Stock-based compensation expense	11,906		11,906			11,906
Issuance of common stock, net of issuance costs (in shares)				5,232,500
Issuance of common stock, net of issuance costs	218,385		218,385			218,385
Issuance of common stock in connection with acquisitions (in shares)				95,019
Issuance of common stock in connection with acquisitions	4,607		4,607			4,607
Forfeiture of restricted stock (in shares)				(4,642)
Forfeiture of restricted stock	(9)		(9)			(9)
Sale of economic interests in majority owned subsidiary, net of taxes	21,191		11,601			11,601			9,590
Contributions from noncontrolling partner	3,927		0						3,927
Change in cumulative foreign currency translation adjustment	(2,198)		(2,198)				(2,198)
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	739		739				739
Net income (loss)	$ 5,410		(2,779)					(2,779)	8,189
Ending balance (in shares) at Mar. 31, 2024	73,901,654			73,901,654
Ending balance at Mar. 31, 2024	$ 1,077,325		$ 872,955	$ 7		$ 969,248	$ (13,943)	$ (82,357)	$ 204,370